Response to comment on ‘SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung’

Alan E. Mast; Alisa S. Wolberg; David Gailani; Michael R. Garvin; Christiane Alvarez; J. Izaak Miller; Piet Jones; Bruce Aronow; Daniel Jacobson

doi:10.7554/eLife.74951

Response to comment on ‘SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung’

Alan E. Mast, Alisa S. Wolberg, David Gailani, Michael R. Garvin, Christiane Alvarez, J. Izaak Miller, Piet Jones, Bruce Aronow, Daniel Jacobson

Computational and Predictive Biology

Research output: Contribution to journal › Letter › peer-review

Abstract

Early in the SARS-CoV-2 pandemic, we compared transcriptome data from hospitalized COVID-19 patients and control patients without COVID-19. We found changes in procoagulant and fibrinolytic gene expression in the lungs of COVID-19 patients (Mast et al., 2021). These findings have been challenged based on issues with the samples (Fitzgerald and Jamieson, 2022). We have revisited our previous analyses in the light of this challenge and find that these new analyses support our original conclusions.

Original language	English
Article number	e74951
Journal	eLife
Volume	11
DOIs	https://doi.org/10.7554/eLife.74951
State	Published - Jan 2022

Funding

Alan E Mast: receives research funding from Novo Nordisk and has received honoraria for serving on Novo Nordisk advisory boards. Alisa S Wolberg: Receives research funding from Takeda and Bristol Myers Squibb. David Gailani: Receives research funding from Bayer and has received honoraria for serving on Anthos, Bristol-Myers Squibb, Ionis and Janssen advisory boards. The other authors declare that no competing interests exist.

Funders	Funder number
National Heart, Lung, and Blood Institute	R35HL140025
Bristol-Myers Squibb
Bayer
Takeda Pharmaceutical Company
Novo Nordisk

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.7554/eLife.74951

Cite this

@article{7228c178713c4401a0bc3667148a9015,

title = "Response to comment on {\textquoteleft}SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung{\textquoteright}",

abstract = "Early in the SARS-CoV-2 pandemic, we compared transcriptome data from hospitalized COVID-19 patients and control patients without COVID-19. We found changes in procoagulant and fibrinolytic gene expression in the lungs of COVID-19 patients (Mast et al., 2021). These findings have been challenged based on issues with the samples (Fitzgerald and Jamieson, 2022). We have revisited our previous analyses in the light of this challenge and find that these new analyses support our original conclusions.",

author = "Mast, {Alan E.} and Wolberg, {Alisa S.} and David Gailani and Garvin, {Michael R.} and Christiane Alvarez and Miller, {J. Izaak} and Piet Jones and Bruce Aronow and Daniel Jacobson",

year = "2022",

month = jan,

doi = "10.7554/eLife.74951",

language = "English",

volume = "11",

journal = "eLife",

issn = "2050-084X",

publisher = "eLife Sciences Publications",

}

TY - JOUR

T1 - Response to comment on ‘SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung’

AU - Mast, Alan E.

AU - Wolberg, Alisa S.

AU - Gailani, David

AU - Garvin, Michael R.

AU - Alvarez, Christiane

AU - Miller, J. Izaak

AU - Jones, Piet

AU - Aronow, Bruce

AU - Jacobson, Daniel

PY - 2022/1

Y1 - 2022/1

N2 - Early in the SARS-CoV-2 pandemic, we compared transcriptome data from hospitalized COVID-19 patients and control patients without COVID-19. We found changes in procoagulant and fibrinolytic gene expression in the lungs of COVID-19 patients (Mast et al., 2021). These findings have been challenged based on issues with the samples (Fitzgerald and Jamieson, 2022). We have revisited our previous analyses in the light of this challenge and find that these new analyses support our original conclusions.

AB - Early in the SARS-CoV-2 pandemic, we compared transcriptome data from hospitalized COVID-19 patients and control patients without COVID-19. We found changes in procoagulant and fibrinolytic gene expression in the lungs of COVID-19 patients (Mast et al., 2021). These findings have been challenged based on issues with the samples (Fitzgerald and Jamieson, 2022). We have revisited our previous analyses in the light of this challenge and find that these new analyses support our original conclusions.

UR - http://www.scopus.com/inward/record.url?scp=85123461458&partnerID=8YFLogxK

U2 - 10.7554/eLife.74951

DO - 10.7554/eLife.74951

M3 - Letter

C2 - 35014952

AN - SCOPUS:85123461458

SN - 2050-084X

VL - 11

JO - eLife

JF - eLife

M1 - e74951

ER -

Response to comment on ‘SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung’

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this